PFK 15

Product Description

PFK 15 is originally reported to be a selective PFKFB3 inhibitor (IC₅₀ = 207 nM); a more recent report failed to demonstrate activity in a PFKFB3 kinase assay. Selective for PFKFB3 over a panel of 96 kinases. Reduces glucose uptake and induces apoptosis in H522 lung adenocarcinoma and Jurkat T cell leukemia cells. Suppresses glucose uptake and tumor growth, and inhibits metastasis of Lewis lung carcinoma cell xenografts in mice.

Solubility

Preparing Stock Solutions for PFK 15

The following data is based on the product molecular weight 260.29

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	3.84 mL	19.21 mL	38.42 mL
5 mM	0.77 mL	3.84 mL	7.68 mL
10 mM	0.38 mL	1.92 mL	3.84 mL
50 mM	0.08 mL	0.38 mL	0.77 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Brooke Targeting the Warburg effect in cancer; relationships for 2-arylpyridazinones as inhibitors of the key glycolytic enzyme 6-phosphofructo-2-kinase/2,6-bisphosphatase 3 (PFKFB3). Bioorg.Med.Chem. 2014 PMID: 24398380
• Clem Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer. Mol.Cancer Ther. 2013 PMID: 23674815